Global Connected Drug Delivery Devices Market : Global Size, Trends, Competitive, And Historical & Forecast Analysis, 2022-2028: Theneed toboostpatientmedicationadherence,accelerationofremotedigital monitoring,andR&Dactivitiesaresomeofthemajorfactorsdrivingthe growthoftheGlobalConnectedDrugDeliveryDevicesMarket.
Global Connected Drug Delivery Devices Market is valued at USD 4.63 Billion in 2021 and expected to reach USD 7.99 Billion by 2028 with a CAGR of 50.21% over the forecast period.
Scope-
In residential settings, connected medication delivery devices are smart wireless electronic solutions that facilitate the monitoring of patients and counselling. They are equipped with adherence trackers, sensors, monitoring systems, dosage reminders, and teaching tools that provide real-time feedback and tailored patient care. They are more affordable and more practical than care obtained in a clinic.
Key Players-
Some major key players for the global Connected Drug Delivery Devices market report cover prominent players like -
• Novo Nordisk A/S
• Teva Respiratory LLC
• Medtronic
• Phillips-Medisize LLC
• Tandem Diabetes Care Inc.
• Adherium Limited
• Propeller health
• Biocorp
• Ypsomed AG
• Aptar Pharma
• others
Segmentation-
By Device Type:
By Technology: • Bluetooth • Near Field Communication • Service
By Application: • Respiratory • Cardiovascular • Anaphylaxis • Hormone Replacement • Diabetes • Others
By
By Regional & Country Level:
U.S.
U.K.
o Brazil
o Mexico
• Middle East and Africa
o GCC
o Africa
o Rest of Middle East and Africa
The
Devices Market Growth
One of the main factors driving the market is the rise in R&D activity. Due to the strong product offerings of numerous important participants, which is predicted to be commercially released throughout the projection period, it also adds to an exponentially growing rate. For instance, in May 2021, Roche, Glooko Inc., DexCom Inc., and myDiabby Healthcare joined up with Eli Lilly and Company to expand connected solutions for diabetics in countries outside of the United States. The firms' diabetes management systems should work with Lilly's Tempo Pen (on the market in many countries across the world) and Tempo Smart Button (in late-stage development), supporting diabetic patients and fostering market expansion.
North America is Expected to Capture a Major Share in the Global Connected Drug Delivery Devices Market
Due to the increased prevalence of chronic illnesses and the existence of a sizable target population, North America is predicted to be the region with the greatest market for linked medication delivery systems. Around 3,600 people per year, according to the Asthma and Allergy Foundation of America. Thus, in these situations, connected drug delivery systems seem to be advantageous for the enhancement of patient adherence to the drugs recommended by doctors, thus boosting the regional market.
The Asia Pacific region is predicted to see the quickest growth during the forecast period due to the higher incidence of chronic illnesses and the availability of a large patient population base. The expansion of the region is also anticipated to be fueled by the expanding number of businesses and initiatives launched by them. For instance, the public business Adherium, which has its headquarters in New Zealand, focuses
need to boost patient medication adherence, acceleration of remote digital monitoring, and R&D activities are some of the major factors driving the growth of the Global Connected Drug Delivery
on creating solutions for monitoring system, data management, and patient adherence in the respiratory industry.
News-
Aptar Pharma Launches HeroTracker Sense
On February 8th, 2022; Aptar Pharma announced the launch of HeroTracker Sense,a breakthrough digital respiratory healthcare system that transforms a typical metered dosage inhaler into a smart linked healthcare system. Aptar Pharma is a global leader in medication delivery devices, services, and active material science solutions.
Jabil Healthcare Announces the Launch of the Qfinity
On May 18th, 2022; A platform named QfinityTM autoinjector was introduced by Jabil Healthcare, a significant international provider of healthcare manufacturing solutions. When compared to other options on the market, this platform offers a reusable and integrated solution for subcutaneous (SC) medication self-administration at a reasonable cost.
Nemera inaugurated a new facility in Lyon
On September 19th, 2022; Nemera has opened a new facility in Lyon, France, which will serve as the company's current European headquarters and innovation hub.